View in EDS HTML Full Text PDF Full Text

Functional Homologous Recombination (HR) Screening Shows the Majority of BRCA1/2-Mutant Breast and Ovarian Cancer Cell Lines Are HR-Proficient.

Saved in:
Bibliographic Details
Title: Functional Homologous Recombination (HR) Screening Shows the Majority of BRCA1/2-Mutant Breast and Ovarian Cancer Cell Lines Are HR-Proficient.
Authors: Meijer TG; Department of Molecular Genetics, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands.; Department of Pathology, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands.; Oncode Institute, 3521 AL Utrecht, The Netherlands., Martens JWM; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands., Prager-van der Smissen WJC; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands., Verkaik NS; Department of Molecular Genetics, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands.; Oncode Institute, 3521 AL Utrecht, The Netherlands., Beaufort CM; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands., van Herk S; Oncode Institute, 3521 AL Utrecht, The Netherlands.; Department of Hematology, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands., Robert-Finestra T; Oncode Institute, 3521 AL Utrecht, The Netherlands.; Department of Developmental Biology, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands., Hoogenboezem RM; Department of Hematology, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands., Ruigrok-Ritstier K; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands., Paul MW; Department of Molecular Genetics, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands.; Oncode Institute, 3521 AL Utrecht, The Netherlands., Gribnau J; Oncode Institute, 3521 AL Utrecht, The Netherlands.; Department of Developmental Biology, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands., Bindels EMJ; Department of Hematology, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands., Kanaar R; Department of Molecular Genetics, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands.; Oncode Institute, 3521 AL Utrecht, The Netherlands., Jager A; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands., van Gent DC; Department of Molecular Genetics, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands.; Oncode Institute, 3521 AL Utrecht, The Netherlands., Hollestelle A; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands.
Source: Cancers [Cancers (Basel)] 2024 Feb 10; Vol. 16 (4). Date of Electronic Publication: 2024 Feb 10.
Publication Type: Journal Article
Journal Info: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101526829 Publication Model: Electronic Cited Medium: Print ISSN: 2072-6694 (Print) Linking ISSN: 20726694 NLM ISO Abbreviation: Cancers (Basel) Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 38398132
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Functional Homologous Recombination (HR) Screening Shows the Majority of BRCA1/2-Mutant Breast and Ovarian Cancer Cell Lines Are HR-Proficient.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Meijer+TG%22">Meijer TG</searchLink>; Department of Molecular Genetics, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands.; Department of Pathology, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands.; Oncode Institute, 3521 AL Utrecht, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Martens+JWM%22">Martens JWM</searchLink>; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Prager-van+der+Smissen+WJC%22">Prager-van der Smissen WJC</searchLink>; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Verkaik+NS%22">Verkaik NS</searchLink>; Department of Molecular Genetics, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands.; Oncode Institute, 3521 AL Utrecht, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Beaufort+CM%22">Beaufort CM</searchLink>; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22van+Herk+S%22">van Herk S</searchLink>; Oncode Institute, 3521 AL Utrecht, The Netherlands.; Department of Hematology, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Robert-Finestra+T%22">Robert-Finestra T</searchLink>; Oncode Institute, 3521 AL Utrecht, The Netherlands.; Department of Developmental Biology, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Hoogenboezem+RM%22">Hoogenboezem RM</searchLink>; Department of Hematology, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Ruigrok-Ritstier+K%22">Ruigrok-Ritstier K</searchLink>; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Paul+MW%22">Paul MW</searchLink>; Department of Molecular Genetics, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands.; Oncode Institute, 3521 AL Utrecht, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Gribnau+J%22">Gribnau J</searchLink>; Oncode Institute, 3521 AL Utrecht, The Netherlands.; Department of Developmental Biology, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Bindels+EMJ%22">Bindels EMJ</searchLink>; Department of Hematology, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Kanaar+R%22">Kanaar R</searchLink>; Department of Molecular Genetics, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands.; Oncode Institute, 3521 AL Utrecht, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Jager+A%22">Jager A</searchLink>; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22van+Gent+DC%22">van Gent DC</searchLink>; Department of Molecular Genetics, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands.; Oncode Institute, 3521 AL Utrecht, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Hollestelle+A%22">Hollestelle A</searchLink>; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101526829%22">Cancers</searchLink> [Cancers (Basel)] 2024 Feb 10; Vol. 16 (4). <i>Date of Electronic Publication: </i>2024 Feb 10.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22MDPI%22">MDPI </searchLink><i>Country of Publication: </i>Switzerland <i>NLM ID: </i>101526829 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Print <i>ISSN: </i>2072-6694 (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2220726694%22">20726694 </searchLink><i>NLM ISO Abbreviation: </i>Cancers (Basel) <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=38398132
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.3390/cancers16040741
    Languages:
      – Code: eng
        Text: English
    Titles:
      – TitleFull: Functional Homologous Recombination (HR) Screening Shows the Majority of BRCA1/2-Mutant Breast and Ovarian Cancer Cell Lines Are HR-Proficient.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Meijer TG
      – PersonEntity:
          Name:
            NameFull: Martens JWM
      – PersonEntity:
          Name:
            NameFull: Prager-van der Smissen WJC
      – PersonEntity:
          Name:
            NameFull: Verkaik NS
      – PersonEntity:
          Name:
            NameFull: Beaufort CM
      – PersonEntity:
          Name:
            NameFull: van Herk S
      – PersonEntity:
          Name:
            NameFull: Robert-Finestra T
      – PersonEntity:
          Name:
            NameFull: Hoogenboezem RM
      – PersonEntity:
          Name:
            NameFull: Ruigrok-Ritstier K
      – PersonEntity:
          Name:
            NameFull: Paul MW
      – PersonEntity:
          Name:
            NameFull: Gribnau J
      – PersonEntity:
          Name:
            NameFull: Bindels EMJ
      – PersonEntity:
          Name:
            NameFull: Kanaar R
      – PersonEntity:
          Name:
            NameFull: Jager A
      – PersonEntity:
          Name:
            NameFull: van Gent DC
      – PersonEntity:
          Name:
            NameFull: Hollestelle A
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 10
              M: 02
              Text: 2024 Feb 10
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-print
              Value: 2072-6694
          Numbering:
            – Type: volume
              Value: 16
            – Type: issue
              Value: 4
          Titles:
            – TitleFull: Cancers
              Type: main
ResultId 1